Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | Unmet needs regarding chemotherapy for prostate cancer

Orazio Caffo • 17 Feb 2023
GU Cancers 2023
Genitourinary Cancer Prostate Cancer Dialuramide Docetaxel

Orazio Caffo, MD, Santa Chiara Hospital, Pisa, Italy, talks on unmet needs regarding chemotherapy for prostate cancer, including with patient selection. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Orazio Caffo

1:01
Updates from ECHOS: real world outcomes from mCSPC treatment with docetaxel
Orazio Caffo • 17 Feb 2023
0:55
Post-progression therapies in patients with mCRPC progressing after docetaxel
Orazio Caffo • 17 Feb 2023
1:12
The first analysis from the ECHOS study of real-world outcomes of docetaxel in patients with mCSPC
Orazio Caffo • 17 Feb 2023
1:48
ECHOS: real-world outcomes of docetaxel in patients with mCSPC
Orazio Caffo • 17 Feb 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals